Background Interleukin (IL)-31 is implicated in pruritus associated with pruritic skin diseases like atopic dermatitis. Although pruritus is a prominent feature in dermatomyositis (DM), few studies have evaluated the pathogenesis of DMassociated itch. Objectives To establish the prevalence of itch in DM, and to investigate the role of IL-31 in DM-related itch. Methods Pruritus and disease activity of DM were evaluated by a visual analogue scale (VAS) and the Cutaneous Disease and Activity Severity Index (CDASI), respectively. Expression of IL-31 and IL-31 receptor alpha (IL-31RA) in lesional DM, nonlesional DM and healthy control skin was evaluated by quantitative reverse-transcriptase polymerase chain reaction and immunofluorescence. Flow cytometry was performed on skin cells isolated from lesional DM skin to identify cellular sources of IL-31 in DM. Results Among 191 patients with DM, 50Á8% had moderate-to-severe itch, and itch was correlated with increased cutaneous severity (r = 0Á34). In patients with itchy DM, gene expression of IL31 and IL31RA in lesional skin was upregulated compared with nonlesional skin and healthy control skin. IL31 mRNA expression positively correlated with VAS itch score (r = 0Á67). On immunofluorescence, immunoreactivity for IL-31 and IL-31RA was stronger in lesional skin. Flow cytometry showed that lesional DM skin contained significantly more IL-31-producing cells, and CD4 + cells were the most common cell type. Lenabasum, an
What is the translational message?
• This study suggests that IL-31 may play a role in the pathogenesis of DM-related pruritus.
• Lenabasum, a new emerging treatment for DM, significantly downregulated IL-31, as well as IL-4, from CpG-stimulated peripheral blood mononuclear cells.
• Ongoing trials will evaluate the effects of systemic treatment on IL-31 and itch in DM.
Dermatomyositis (DM) is an autoimmune disease that frequently involves skin, muscle and/or lung. Pruritus is one of the prominent cutaneous features in DM, and can help distinguish patients with DM from those with lupus erythematosus clinically. 1, 2 Although one case review studied 20 patients with juvenile DM and found that 38% complained of pruritus, 3 there is a paucity of quantitative studies of pruritus in DM. Shirani et al. 4 observed a significant itch sensation in a majority of their patient population, but the number of patients studied was limited and the questionnaire was anonymous, preventing analysis of correlations with other disease characteristics. Dermatological aspects of DM, especially pruritus, have a significant impact on quality of life, rendering management of pruritus important in patients with DM. 1, 5 However, neither the extent of itch in this population nor the pathogenesis of the itch associated with DM has been clearly understood.
Interleukin (IL)-31 is a short-chain four-helix bundle cytokine that is important for both innate and adaptive immunity in the skin. IL-31 is expressed mostly by activated CD4 + T cells, and preferentially by T cells skewed towards a T helper (Th)2 phenotype. 6, 7 Mast cells and a subset of the monocytemacrophage population also produce IL-31. [8] [9] [10] IL-31 signals through a heterodimeric receptor composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRb). 6 A variety of cell types, like activated monocytes, macrophages, eosinophils, basophils, dorsal root ganglion (DRG) and keratinocytes, express the IL-31 receptor complex.
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IL-31 has been incriminated in pruritus in humans and mice. When overexpressed in transgenic mice or cutaneously injected, IL-31 causes dermatitis, alopecia and pruritus.
6,12 IL-31 mRNA and protein are increased in pruritic human skin diseases, including atopic dermatitis (AD), allergic contact dermatitis and prurigo nodularis. 13 IL-31, IL-31RA and OSMRb were elevated in the epidermis of affected cutaneous T-cell lymphoma (CTCL) skin and IL-31 expression was significantly correlated with the severity of itch.
14 Recently, lenabasum (JBT-101) has been studied as a new potential treatment option for DM. Lenabasum is a nonpsychoactive analogue of tetrahydrocannabinol that selectively binds proresolving receptor on immune cells. Lenabasum suppressed inflammatory cytokines, including tumour necrosis factor (TNF)-a, interferon (IFN)-a and IFN-b, which are important in the pathogenesis of DM. 15 We hypothesized that lenabasum could also inhibit IL-31 secretion, contributing to its therapeutic effect. Our goals were to establish the prevalence and severity of itch in patients with DM, and to determine any differences in itch related to sex or DM subtype. We further investigated the presence of IL-31 in the skin of patients with DM, its relationship with itch severity, and the cellular source of IL-31, to explain the pathogenic mechanism of itch in these patients. We also evaluated the suppressive effect of lenabasum on IL-31 secretion in peripheral blood mononuclear cells (PBMCs) from patients with DM.
Patients and methods

Patients
In total, 191 patients with DM seen at the dermatology clinic of the Hospital of the University of Pennsylvania were included in the study, regardless of whether or not they were currently undergoing treatment. Information regarding age, sex and subtype of DM [classic DM (CDM); clinically amyopathic DM (CADM)] was recorded. A patient was diagnosed with CDM when they had characteristic DM skin lesions together with muscle symptoms such as muscle weakness or difficulty standing from a sitting position or walking upstairs, along with electromyogram or magnetic resonance imaging documenting muscle involvement. If the patient had only skin symptoms without muscle symptoms, even if muscle enzymes such as creatinine kinase and aldolase were elevated, the patient was diagnosed as having CADM. Skin symptoms characteristic of DM included Gottron papules and sign; heliotrope rash; violaceous erythema including shawl sign, V sign and holster sign; and mechanic's hands.
Skin tissue samples were collected from 15 patients with DM and four healthy controls. In patients with DM, lesional skin consisted of erythematous patches. Exclusion criteria for skin sampling and information about healthy controls are detailed in Appendix S1 (see Supporting Information). The experimental protocol was approved by the ethics committee of the University of Pennsylvania and conformed to the principles outlined in the Declaration of Helsinki. Written informed consent was given by every patient involved in the study.
Measurement of pruritus and dermatomyositis cutaneous disease severity
The severity of pruritus was measured using a 10Á0-cm visual analogue scale (VAS), with one end representing no itch and the other representing maximum itch. 16 The VAS scores were divided into four groups for analysis: no pruritus (score of 0 on the VAS), mild pruritus (score 1Á0-3Á3), moderate pruritus (score 3Á4-6Á6) and severe pruritus (score 6Á7-10Á0). 4 The severity of cutaneous disease was evaluated using the Cutaneous Disease and Activity Severity Index (CDASI), which is a validated disease severity score of DM. CDASI activity scores range from 0 to 100 and damage scores from 0 to 32. We considered scores < 14 as mild disease. 17 RNA isolation and quantitative real-time reversetranscriptase polymerase chain reaction
The methods are available in Appendix S1 (see Supporting Information).
Immunofluorescence
Skin cell isolation and flow cytometry
To analyse the cellular source of IL-31 in skin, fresh skin tissues were obtained by 6-mm punch biopsy from lesional skin of three patients with itchy DM and four healthy controls, and cells were isolated as described previously. 18 To assess IL-31 production, the isolated cells were cultured in the presence of phorbol 12-myristate 13-acetate-ionomycin and brefeldin A for a total of 5 h. Single-cell suspensions underwent flow cytometric analysis on an LSR-II flow cytometer (BD Biosciences, San Jose, CA, U.S.A.) and were analysed with FlowJo software (Tree Star, Inc., Ashland, OR, U.S.A.). In total, 50 000 events were collected for analysis. Events were gated on single, live cell populations, and IL-31 production was assessed in CD3 + CD4 + , CD3 + CD8 + , CD11b + , CD11c + and CD68 + cells. Detailed methods are described in Appendix S1
(see Supporting Information).
Lenabasum
An ultrapure powder formulation of lenabasum was used in this study (Corbus Pharmaceuticals Holdings, Norwood, MA, U.S.A.). The lenabasum was dissolved in 100% dimethyl sulfoxide.
Peripheral blood mononuclear cell isolation, lenabasum treatment and quantification of interleukin-31, interleukin-4 and transforming growth factor-b secretion
To see whether lenabasum could inhibit IL-31 secretion in patients with DM, PBMCs were isolated from heparinized venous blood of eight patients with DM. Full details are available in Appendix S1 (see Supporting Information 
Statistical analysis
The Mann-Whitney test, the Spearman rank test and the Kruskal-Wallis test with Dunn's post hoc test were used. Statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, U.S.A.). A two-tailed P-value < 0Á05 was considered significant in all statistical analyses. Further details are available in Appendix S1 (see Supporting Information).
Results
Patient characteristics
Among 191 patients (28 male, 163 female, mean age 50Á9 AE 13Á3 years), 73 had CDM with active muscle involvement, and 118 had CADM. Among all the patients, 9Á4% had no itch, 39Á8% had mild itch, 28Á8% had moderate itch and 22Á0% had severe itch. Although the finding was not statistically significant, female patients tended to experience more itch than male patients (median VAS: female 4Á0 vs. male 1Á9, P = 0Á52) (Fig. 1a) . Among female patients, 52Á1% had moderate-to-severe pruritus, compared with 43% of men. The difference in median VAS itch score between subtypes of DM was not statistically significant (CDM 3Á3 vs. CADM 3Á95, P = 0Á77) (Fig. 1b) .
Correlation between pruritus and skin severity of dermatomyositis
Pruritus scores in all patients significantly correlated with CDASI activity scores (correlation coefficient r = 0Á35, P < 0Á001), suggesting that itch is correlated with increased cutaneous severity. CDASI damage score did not show a correlation with itch (r = 0Á10, P = 0Á16). When evaluated according to the subtype of DM, itch scores in both the CDM and CADM groups showed a significant correlation with the CDASI activity score (CDM r = 0Á32, P = 0Á0065; CADM r = 0Á37, P < 0Á001), but not with the CDASI damage score (CDM r = 0Á17, P = 0Á16; CADM r = 0Á05, P = 0Á60) (Fig. 1c , Fig. S1 ; see Supporting Information).
Upregulated gene expression of IL31 and IL31RA in lesional skin of dermatomyositis and correlation with visual analogue scale itch score
In 12 patients with DM with pruritus, gene expression of IL31 and IL31RA in lesional skin was compared with the patients' nonlesional skin and skin samples from healthy controls. The mRNA levels of IL31 were significantly higher in lesional DM skin than in nonlesional DM skin and healthy control skin (Fig. 2a) . IL31RA gene expression was enhanced in lesional DM skin in comparison with healthy control skin (Fig. 2b) . Lesional-skin IL31 expression was positively correlated with VAS itch score (r = 0Á59, P = 0Á044) (Fig. 2c) , while correlation between IL31RA expression and itch score was not statistically significant (r = 0Á20, P = 0Á58). To rule out the effects of other cytokines dominant in DM, we evaluated gene expression of IL4 and its correlation with IL31. As previously noted, 19, 20 IL4 expression was significantly upregulated in lesional DM skin compared with healthy control skin (Fig. 2d) . However, it did not correlate with VAS itch score (Fig. 2e) .
Interleukin-31 expression is increased in lesional dermatomyositis skin compared with nonlesional dermatomyositis and healthy control skin
Immunofluorescence revealed that lesional DM skin has a higher area fraction and mean fluorescence intensity (MFI) of IL-31 than nonlesional DM skin and healthy control skin (Fig. 3a, c,  e, g ). Double staining of CD4 and IL-31 showed colocalization, suggesting that at least some of the IL-31-producing cells were CD4 + cells in patients with DM (Fig. 3a) . The area fraction and MFI of IL-31RA were increased in lesional skin compared with healthy control skin (Fig. 3b, d , f, h). Correlation between visual analogue scale (VAS) itch score and Cutaneous Disease and Activity Severity Index (CDASI) activity score (CDM r = 0Á32, P = 0Á0065; CADM r = 0Á37, P < 0Á001).
Published [2018] . This article is a U.S. Government work and is in the public domain in the USA.
British Journal of Dermatology (2018) 179, pp669-678
were not CD4 + cells (Fig. 3a) . To identify other cellular sources of IL-31 in DM, we performed flow cytometry on single-cell suspensions of lesional DM skin using CD4, CD8, CD11b, CD11c and CD68 as cell population markers. Our results showed that the inflammatory cell population in lesional DM skin contained significantly increased percentages of IL-31-producing cells compared with healthy control skin (Fig. 4a, b) . CD4 + cells were the most common cell types to produce IL-31 in DM, but other cell types that express CD8, CD68, CD11b or CD11c also secreted IL-31 in DM. The proportion of each inflammatory cell type, a percentage of which were found to produce IL-31 in patients with DM, was similar in lesional DM and healthy control skin. Although CD4 + cells and CD8 + cells were approximately two times more common in lesional DM skin than in healthy control skin, the increase was much more prominent in the IL-31-producing population (Fig. 4c) populations. In addition, the MFI of IL-31-producing cells was also higher in lesional skin than in healthy control skin in all cell types studied (Fig. 4d) . Moderate and high lenabasum concentrations suppressed secretion of interleukin-31 and interleukin-4 by CpG-stimulated peripheral blood mononuclear cells
To evaluate the suppressive effect of lenabasum on the production of cytokines important in DM, PBMCs were isolated from eight patients with DM and eight healthy controls, and were stimulated by CpG with or without lenabasum treatment. Levels of IL-31, IL-4 and TGF-b were subsequently evaluated by ELISA. CpG-mediated induction of IL-31 in PBMCs was significantly higher in patients with DM than in healthy controls (Fig. 5a ). Lenabasum significantly suppressed the production of IL-4 and IL-31 by CpG-stimulated PBMCs isolated from patients with DM at concentrations of 10 and 15 lmol L À1 (P < 0Á05) ( c). Lenabasum did not inhibit TGF-b secretion by CpG-stimulated PBMCs at any concentration (Fig. 5d ).
Discussion
Common cutaneous symptoms of DM include pruritus and photosensitivity. In one study, the mean VAS itch score was consistently over 5Á0, placing the majority of the study population in the moderate-to-severe itch categories (VAS score > 3Á4). 4 In this study, > 90% of patients with DM had pruritus, with just over half experiencing moderate-to-severe itch. The severity of itch correlated with disease activity, but not with disease damage. The extensive prevalence of itch and the strong correlation of itch severity with disease activity in patients with DM indicate that management of itch is an important component of overall DM treatment. 1, 4 However, the pathogenesis of DM-related itch remains largely unknown. IL-31 is an IL-6-family cytokine, and works by binding to the IL-31 receptor complex. Subsequent signalling is through the Janus kinase-signal transducer and activator of transcription pathway, the phosphoinositide-3-kinase-Akt pathway and the mitogen-activated protein kinase pathway. 8, 21 IL-31 has a wide range of biological functions, including the regulation of immune responses; induction of chemokines, signal proteins and proinflammatory cytokines; regulation of cell proliferation; and, most prominently, induction of itch. 11, 22 IL-31 has been incriminated in pruritus in humans and mice. Scratching behaviour was increased in transgenic mice overexpressing IL-31, and in IL-31-injected mice and dogs. 6, 23 IL-31expression is increased in the lesional skin of patients with itchy skin disorders, such as AD. 7, 24 Studies report a correlation of serum IL-31 levels with disease activity in AD. 13, 25, 26 Serum IL-31 levels were increased in patients with chronic spontaneous urticaria compared with healthy controls, but were lower than in patients with AD. 27 IL-31 was also increased in the serum of patients with CTCL, and the levels were increased in advanced CTCL disease. [28] [29] [30] Patients with uraemic pruritus also had higher serum IL-31 than those without pruritus. 31 As a therapeutic option for pruritus, a monoclonal anti-IL-31 antibody was reported to reduce scratching behaviour and dermatitis in a mouse model of AD. 32 Recently, a humanized antihuman IL-31RA antibody successfully reduced pruritus in patients with AD, suggesting that IL-31 could potentially be a good target for pruritus in AD and other pruritic diseases. The exact mechanism of how IL-31 mediates itch is still not clear. IL-31 receptors are present on DRG in humans and mice, and cutaneously injected IL-31-induced itching was enhanced by DRG IL-31RA expression in mice. 6, 12, 34 19, 20 Our epidemiological data confirming the predominance of itch in DM, along with the increased Th2 cells in DM, led us to examine the possible role of IL-31 in DM itch. In this study, we found that skin IL-31 gene and protein expression was higher in patients with DM than in healthy controls, with a correlation between the itch intensity and skin IL-31 levels. CpG-induced IL-31 levels in PBMCs were also higher in patients with DM than in healthy controls. Immunohistochemical studies of lesional DM skin demonstrated colocalization of CD4 and IL-31 on cells. Flow cytometry showed that lesional DM skin had a significantly larger population of IL-31-producing cells than healthy control skin. While CD4 + cells were identified as the most common cell types to produce IL-31 in DM, other cell types expressing CD8, CD68, CD11b or CD11c were also able to secrete IL-31. How IL-31 production is regulated in these cells in DM is not known. As monocytes and macrophages are known to produce IL-31, 9,10 and they express IL-4 receptors, 38, 39 stimulation by IL-4 or a different pathway that stimulates IL-31 could be responsible for IL-31 production by these cells. Recently, lenabasum (JBT-101), an investigational, nonpsychoactive and anti-inflammatory cannabinoid, was found to suppress secretion of TNF-a, IFN-a and IFN-b from immune cells of patients with DM in vitro. 15 These cytokines are thought to be key immunostimulatory cytokines contributing to the inflammation seen in cutaneous DM. Prior data from animal studies and phase I clinical trials have led to an ongoing phase II study of lenabasum in patients with DM with significant skin disease. In the present study, lenabasum significantly suppressed the secretion of IL-4 and IL-31 from CpG-stimulated PBMCs in vitro, indicating its potential as a new therapy for itch in DM. Because Th2 cells are a major source of IL-31, and because IL-31 production is dependent on IL-4 secretion by Th2 cells, 37 suppression of IL-4 and IL-31 by lenabasum could be the mechanism by which lenabasum reduces clinical disease activity in DM. The TGF-b1-IL-31 pathway is known to play an important role in cell injury and inflammation in hepatitis B virus-related liver injury. 40, 41 Although TGF-b was significantly upregulated in DM compared with controls, 20, 42 and lenabasum successfully inhibited TGF-b in scleroderma, 43, 44 lenabasum did not suppress TGF-b production by PBMCs isolated from patients with DM in the present study, implying that its suppressive effects on IL-31 are independent of the TGF-b-IL-31 pathway.
In conclusion, we have confirmed that itch is a refractory, prevalent and problematic symptom in many patients with DM involving the skin. Skin IL-31 is significantly higher in patients with itchy DM than in healthy controls, implicating its possible role in itch associated with DM.
